TITLE

Patent battle over AZT heats up

AUTHOR(S)
Joyce, Christopher
PUB. DATE
June 1991
SOURCE
New Scientist;6/8/91, Vol. 130 Issue 1772, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Details a dispute between the National Institutes of Health (NIH) in America and the British company Burroughs Wellcome, over patent rights to the AIDS drug zidovudine (also known as Retrovir and AZT). Possible lawsuit by the NIH for a share in the patent; History of the dispute; Performance of crucial assays at the NIH; Response of Kathy Bartlett, a spokesperson for Burroughs Wellcome.
ACCESSION #
9107152395

 

Related Articles

  • Efavirenz/lamivudine/zidovudine.  // Reactions Weekly;2/14/2009, Issue 1239, p14 

    The article describes the case of a man with AIDS who developed immune reconstitution syndrome leading to an exacerbation of tuberculosis during treatment with efavirenz, lamivudine and zidovudine. The man was diagnosed with pulmonary tuberculosis and AIDS and started receiving antituberculars...

  • AZT Used to Treat People with AIDS. Pantalone, David W. // LGBT History, 1976-1987;2005, p15 

    Because of promising findings, the U.S. Food and Drug Administration ended a clinical trial of AZT early and released the experimental drug so that it could be prescribed to people with AIDS.

  • Interferon-α with Zidovudine: Safety, Tolerance, and Clinical and Virologic Effects in Patients with Kaposi Sarcoma Associated with the Acquired Immunodeficiency Syndrome (AIDS). Krown, Susan E.; Gold, Jonathan W. M.; Niedzwiecki, Donna; Bundow, Denise; Flomenberg, Neal; Gansbacher, Bernd; Brew, Bruce J. // Annals of Internal Medicine;6/1/90, Vol. 112 Issue 11, p812 

    Evaluates the safety, tolerance and potential efficacy of interferon-α and zidovudine combination therapy in patients with Kaposi sarcoma and AIDS. Description of interferon-α and zidovudine; Distinction of the mechanism of virus inhibition of zidovudine from that of interferon-α;...

  • Feds secure AZT for PWA's . Popert, Ken // Body Politic;Dec86, Issue 133, p15 

    Reports that AZT, a drug which has been shown to slow the progress of AIDS in infected individuals, will soon be available in Canada. Highlights of the study conducted by Burroughs Wellcome Co., the U.S. pharmaceutical firm which owns the rights to AZT; Impact of the U.S. announcement of the...

  • The Effect of the Interaction of Acyclovir with Zidovudine on Progression to AIDS and Survival. Stein, Daniel S.; Graham, Neil M. H.; Park, Lawrence P.; Hoover, Donald R.; Phair, John P.; Detels, Roger; Ho, Monto; Saah, Alfred J. // Annals of Internal Medicine;7/15/94, Vol. 121 Issue 2, p100 

    Objective: To examine the effect of acyclovir use on disease progression and survival in human immunodeficiency virus (HIV)-seropositive persons treated with zidovudine. Setting: Four university-based or -affiliated clinics. Design: Prospective cohort study of homosexual and bisexual men with...

  • ZDV.  // Taber's Cyclopedic Medical Dictionary;2005, p2367 

    The article presents a definition for the term "ZDV," which refers to Zidovudine, an antiviral drug used in the treatment of HIV.

  • No study has measured the effect of early AZT use on survival. Delaney, Martin // Advocate;4/7/92, Issue 600, p31 

    Focuses on the confusion among AIDS patients and physicians regarding the use of the drug AZT which was brought about by a research study published in the February 1992 edition of the periodical 'New England Journal of Medicine.' Conclusions made by researchers; Flaws in the research study methods.

  • New Data on the Limits of AZT.  // Advocate;12/8/87, Issue 487, p23 

    Reports on the report of physicians from the University of Miami School of Medicine on the negative effects of the AIDS drug AZT on the first patients that received the treatment. Weight loss and T cell decline in the patients under the study; Development of serious opportunistic infections.

  • OKLAHOMA.  // Advocate;11/3/92, Issue 615, p26 

    Reports that Oklahoma state-subsidized distribution of the antiviral drug, AZT to indigent people will be stopped because of a bureaucratic problem that caused officials at state agencies to fail to report that the program was in jeopardy.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics